Faculty Opinions recommendation of Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Patients with Union for International Cancer Control (UICC) stage IV colorectal cancer have poor outcomes; 5-year-survival rates are only about 6%. Treatment of unresectable tumors in this setting using 5-fluorouracil (5-FU) and leucovorin extends median overall survival from 6 to 12 months {1}. This study, together with {2,3}, found that the addition of biologicals, such as the vascular endothelial growth factor A (VEGF-A) antibody, bevacizumab or epithelial growth factor receptor (EGFR) antibodies cetuximab and panitumumab, to standard regimens led to overall survival times of about 24 months. This Recommendation is of an article referenced in an F1000Prime Report also written by Sebastian Stintzing.